This drug belongs to the 4-nitrogen steroid hormone compound and is a specific type II 5alpha;-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the levels of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia by reducing the levels of dihydrotestosterone in the blood and prostate tissues, and improves the related clinical symptoms of benign prostatic hyperplasia.

This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased.

The antipsychotic effect is mainly related to its blocking of dopamine receptors (DA2) in the mesolimbic system and mesocortical pathways related to emotional thinking, while blocking the alpha-adrenaline receptors in the reticular formation ascending activation system is related to the sedative and tranquilizing effect. This product has a strong antiemetic effect and a weak sedative effect.

The antipsychotic effect is mainly related to its blocking of dopamine receptors (DA2) in the mesolimbic system and mesocortical pathways related to emotional thinking, while blocking the alpha-adrenaline receptors in the reticular formation ascending activation system is related to the sedative and tranquilizing effect. This product has a strong antiemetic effect and a weak sedative effect.